A glycinate derivative of alpha-
methylprednisolone (MP) was prepared and conjugated to a linear
cyclodextrin polymer (
CDP) with a loading of 12.4% w/w. The
polymer conjugate (
CDP-MP) self-assembled into nanoparticles with a size of 27 nm. Release kinetics of MP from the
polymer conjugate showed a half-life (t1/2) of 50 h in
phosphate buffer solution (PBS) and 19 h in human plasma. In vitro, the proliferation of human lymphocytes was suppressed to a similar extent but with a delayed effect when
CDP-MP was compared with free MP. In vivo,
CDP-MP was administered intravenously to mice with
collagen-induced arthritis and compared with free MP.
CDP-MP was administered weekly for six weeks (0.07, 0.7, and 7 mg/kg/week) and MP was administered daily for six weeks (0.01, 0.1, and 1 mg/kg/day).
Body weight changes were minimal in all animals. After 28 days, a significant decrease in
arthritis score was observed in animals treated weekly with an intermediate or high dose of
CDP-MP. Additionally, dorsoplantar swelling was reduced to baseline in animals treated with
CDP-MP at the intermediate and high dose level. Histological evaluation showed a reduction in
synovitis, pannus formation and disruption of architecture at the highest dose level of
CDP-MP. MP administered daily at equivalent cumulative doses showed minimal efficacy in this model. This study demonstrates that conjugation of MP to a
cyclodextrin-polymer may improve its efficacy, leading to lower doses and less frequent administration for a safer and more convenient management of
rheumatoid arthritis.